Literature DB >> 16485262

Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia.

Ibone Huerta1, Robert E McCullumsmith, Vahram Haroutunian, José Manuel Giménez-Amaya, James H Meador-Woodruff.   

Abstract

The excitatory amino acid transporters (EAATs) are a family of plasma membrane proteins that maintain synaptic glutamate concentration by removing glutamate from the synaptic cleft. EAATs are expressed by glia (EAAT1 and EAAT2) and neurons (EAAT3 and EAAT4) throughout the brain. Glutamate reuptake is regulated, in part, by EAAT-interacting proteins that modulate subcellular localization and glutamate transport activity of the EAATs. Several lines of investigation support the hypothesis of glutamatergic abnormalities in schizophrenia. Previous work in our laboratory demonstrated increased expression of EAAT1 and EAAT2 transcripts in the thalamus, suggesting that alterations in synaptic glutamate levels may contribute to the pathophysiology of schizophrenia. Since EAAT-interacting proteins regulate EAAT function, directly impacting glutamatergic neurotransmission, we hypothesized that expression of EAAT-interacting proteins may also be altered in schizophrenia. Using in situ hybridization in subjects with schizophrenia and a comparison group, we detected increased expression of JWA and KIAA0302, molecules that regulate EAAT3 and EAAT4, respectively, in the thalamus in schizophrenia. In contrast, we did not find changes in the expression of transcripts for the EAAT2 and EAAT4 regulatory proteins GPS-1 and ARHGEF11. To address prior antipsychotic treatment in our schizophrenic subjects, we treated rats with haloperidol and clozapine for 4 weeks, and found changes in transcript expression of the EAAT-interacting proteins in clozapine-, but not haloperidol-, treated rats. These findings suggest that proteins associated with the regulation of glutamate reuptake may be abnormal in this illness, supporting the hypothesis of altered thalamic glutamatergic neurotransmission in schizophrenia. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16485262     DOI: 10.1002/syn.20250

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  22 in total

1.  Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia.

Authors:  Pavel Katsel; William Byne; Panos Roussos; Weilun Tan; Larry Siever; Vahram Haroutunian
Journal:  Neuropsychopharmacology       Date:  2011-01-26       Impact factor: 7.853

2.  Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia.

Authors:  Dan Shan; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Neuroreport       Date:  2012-03-07       Impact factor: 1.837

3.  Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia.

Authors:  Deborah Bauer; Daya Gupta; Vahram Harotunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2008-08-03       Impact factor: 4.939

Review 4.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

5.  Localization of excitatory amino acid transporters EAAT1 and EAAT2 in human postmortem cortex: a light and electron microscopic study.

Authors:  R C Roberts; J K Roche; R E McCullumsmith
Journal:  Neuroscience       Date:  2014-07-24       Impact factor: 3.590

Review 6.  Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.

Authors:  Joseph T Coyle; Alo Basu; Michael Benneyworth; Darrick Balu; Glenn Konopaske
Journal:  Handb Exp Pharmacol       Date:  2012

Review 7.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

8.  Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia.

Authors:  Amy E Steffek; Robert E McCullumsmith; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2008-06-17       Impact factor: 4.939

9.  Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia.

Authors:  Akin Oni-Orisan; Lars V Kristiansen; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Biol Psychiatry       Date:  2007-12-26       Impact factor: 13.382

Review 10.  Thalamic nuclear abnormalities as a contributory factor in sudden cardiac deaths among patients with schizophrenia.

Authors:  Fulvio A Scorza; Andrea Schmitt; Roberta M Cysneiros; Ricardo M Arida; Esper A Cavalheiro; Wagner F Gattaz
Journal:  Clinics (Sao Paulo)       Date:  2010-05       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.